Evidence map›Paper›PMID 23035049›Full record

ArticleHuman molecular genetics2013

Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human Leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants.

Samuel G Jacobson, Artur V Cideciyan, Igor V Peshenko, Alexander Sumaroka, Elena V Olshevskaya, Lihui Cao, Sharon B Schwartz, Alejandro J Roman, Melani B Olivares, Sam Sadigh and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 100 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Veterinary sciences · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. cGMP Signaling in Photoreceptor Degeneration.International journal of molecular sciences · 2023
    Review
  12. Preclinical studies in support of phase I/II clinical trials to treatMolecular therapy. Methods & clinical development · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Leber Congenital Amaurosis Due toInternational journal of molecular sciences · 2021
    Article
  20. Current Clinical Applications of In Vivo Gene Therapy with AAVs.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Samuel G JacobsonScheie Eye Institute, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA. jacobsos@mail.med.upenn.edu
Artur V Cideciyan
Igor V Peshenko
Alexander Sumaroka
Elena V Olshevskaya
Lihui Cao
Sharon B Schwartz
Alejandro J Roman
Melani B Olivares
Sam Sadigh
King-Wai Yau
Elise Heon
Edwin M Stone
Alexander M Dizhoor
Penn Presbyterian Medical Center · USSalus University · USUniversity of Pennsylvania · USHospital for Sick Children · CAHoward Hughes Medical Institute · USJohns Hopkins Medicine · USJohns Hopkins University · US

Funding

REGULATION OF CYCLIC GMP SYNTHESIS IN PHOTORECEPTORSR01EY011522 · NEI · WAYNE STATE UNIVERSITY · PI ALEXANDER M DIZHOOR · 1996 to 2026
$9.9M
NEI NIH HHS EY11522
6 · The paper itself

Abstract

The GUCY2D gene encodes retinal membrane guanylyl cyclase (RetGC1), a key component of the phototransduction machinery in photoreceptors. Mutations in GUCY2D cause Leber congenital amaurosis type 1 (LCA1), an autosomal recessive human retinal blinding disease. The effects of RetGC1 deficiency on human rod and cone photoreceptor structure and function are currently unknown. To move LCA1 closer to clinical trials, we characterized a cohort of patients (ages 6 months-37 years) with GUCY2D mutations. In vivo analyses of retinal architecture indicated intact rod photoreceptors in all patients but abnormalities in foveal cones. By functional phenotype, there were patients with and those without detectable cone vision. Rod vision could be retained and did not correlate with the extent of cone vision or age. In patients without cone vision, rod vision functioned unsaturated under bright ambient illumination. In vitro analyses of the mutant alleles showed that in addition to the major truncation of the essential catalytic domain in RetGC1, some missense mutations in LCA1 patients result in a severe loss of function by inactivating its catalytic activity and/or ability to interact with the activator proteins, GCAPs. The differences in rod sensitivities among patients were not explained by the biochemical properties of the mutants. However, the RetGC1 mutant alleles with remaining biochemical activity in vitro were associated with retained cone vision in vivo. We postulate a relationship between the level of RetGC1 activity and the degree of cone vision abnormality, and argue for cone function being the efficacy outcome in clinical trials of gene augmentation therapy in LCA1.

Indexed as

Mutation, MissenseAdolescentAdultCatalytic DomainChildChild, PreschoolCohort StudiesFemaleGuanylate CyclaseHumansInfantLeber Congenital AmaurosisMalePhotoreceptor Cells, VertebrateReceptors, Cell SurfaceRetinal Cone Photoreceptor CellsGuanylate Cyclaseguanylate cyclase 1Receptors, Cell Surface

Identifiers

PMID23035049
PMCPMC3606011
OpenAlexW2149667682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.